Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This study will test the hypothesis that early use of combination therapy with dapagliflozin
and metformin will provide good glycemic control with low glycemic variability and without
hypoglycemic episodes, and will be better tolerated than up-titration of metformin
monotherapy. The study will also correlate these benefits with glycated hemoglobin.
Phase:
Phase 4
Details
Lead Sponsor:
Research Clinical Centre of the Russian Railways, JSC